(Q35790897)

10 August 2017

1 reference

title

Novel biologic therapies for psoriasis (English)

1 reference

10 August 2017

Jane Barry

1

1 reference

10 August 2017

Brian Kirby

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

975-987

1 reference

The immunologic basis for the treatment of psoriasis with new biologic agents

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Cross-reactivity between streptococcal M surface antigen and human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Treatment targeted to cell surface epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Inflammatory skin diseases, T cells, and immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

The inflammatory infiltrate in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

CD4 antibody treatment of severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

CD28/CTLA-4 and CD80/CD86 families: signaling and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Novel immune-based therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

The ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.6.975

21 January 2018

Identifiers

DOI

10.1517/14712598.4.6.975

1 reference

10 August 2017

1 reference